Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: A phase II, observer-blind, randomized, controlled trial.
Saved in:
| Title: | Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: A phase II, observer-blind, randomized, controlled trial. |
|---|---|
| Authors: | Madan, Anuradha1 Anu.2.Madan@gsk.com, Ferguson, Murdo2, Rheault, Paul3, Seiden, David4, Toma, Azhar5 azhar.toma@mannaresearch.com, Friel, Damien6 damien.j.friel@gsk.com, Soni, Jyoti7, Li, Ping1 ping.li4@pfizer.com, Innis, Bruce L.1 bruce.2.innis@gsk.com, Schuind, Anne1 |
| Source: | Vaccine. Apr2017, Vol. 35 Issue 15, p1865-1872. 8p. |
| Database: | Environment Complete |
Be the first to leave a comment!
